Vericel reports record Q4 gross margin 78%, FY2024 revenue up 20% to $237M, net income positive

Vericel Corp

2024-FY EPS reported $0.20 revenue$237,224,000

Full-year 2024 revenue $237.2M (+20% YoY); MACI $197.3M (+20%), Burn Care $39.9M (+22%).
Q4 GAAP net income $19.8M ($0.38 diluted EPS) vs $13.0M YoY; adjusted EBITDA margin 40%.
FY2024 adjusted EBITDA $53.4M (23% margin), up 58% YoY; operating cash flow $58.2M.
2025 guidance: revenue growth 20-23%, gross margin 73-74%, adj. EBITDA margin 25-26%.
MACI Arthro launch traction: ~250 surgeons trained; NexoBrid orders +42% QoQ; new facility on track.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.